Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
onfekafusp alfa + dacarbazine
- Development stage
- Unknown
- Lead developer
- Philogen
- Modality
- Small Molecules, Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Onfekafusp alfa + dacarbazine is an investigational anticancer combination therapy studied primarily in advanced or metastatic soft tissue sarcoma. Onfekafusp alfa (also known as L19-TNF or Fibromun) is a fully human antibody–cytokine fusion protein, consisting of an anti–extra domain-B (EDB) human antibody (L19) fused to human tumor necrosis factor alpha (TNF-α). The L19 antibody targets the EDB domain of fibronectin, selectively localizing TNF activity to tumor neovasculature, thereby increasing vascular permeability and potentiating immune-mediated and direct cytotoxic tumor cell killing. Dacarbazine (DTIC) is a standard chemotherapeutic alkylating agent that induces DNA damage in proliferating cells. The combination aims to exploit complementary mechanisms: TNF-mediated vascular disruption and immune potentiation (onfekafusp alfa), and direct cytotoxicity (dacarbazine), with the goal of improving therapeutic efficacy in sarcoma and possibly other tumoral indications[1][3][4][5].
- Brand names
- Fibromun + dacarbazine
- Other names
- onfekafusp alfa + dacarbazineL19TNF + dacarbazineL19-TNF + dacarbazineFibromun + dacarbazine
02
Targets
DNAED-B (Fibronectin extra domain B)TNFR (TNF receptor family)
Beyond the preview
Go deeper on onfekafusp alfa + dacarbazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on onfekafusp alfa + dacarbazine.